Joerg Thomas Bittenbring

1.7k total citations
56 papers, 828 citations indexed

About

Joerg Thomas Bittenbring is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Joerg Thomas Bittenbring has authored 56 papers receiving a total of 828 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 23 papers in Oncology and 16 papers in Immunology. Recurrent topics in Joerg Thomas Bittenbring's work include Lymphoma Diagnosis and Treatment (19 papers), Immune Cell Function and Interaction (11 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Joerg Thomas Bittenbring is often cited by papers focused on Lymphoma Diagnosis and Treatment (19 papers), Immune Cell Function and Interaction (11 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Joerg Thomas Bittenbring collaborates with scholars based in Germany, United States and France. Joerg Thomas Bittenbring's co-authors include Michael Pfreundschuh, Frank Neumann, Gerhard Held, Evi Regitz, Marita Ziepert, Manfred Ahlgrimm, Niels Murawski, Klaus‐Dieter Preuss, Ulrich Laufs and Mathias Hänel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Joerg Thomas Bittenbring

54 papers receiving 814 citations

Peers

Countries citing papers authored by Joerg Thomas Bittenbring

Since Specialization

Citations

This map shows the geographic impact of Joerg Thomas Bittenbring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joerg Thomas Bittenbring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joerg Thomas Bittenbring more than expected).

Fields of papers citing papers by Joerg Thomas Bittenbring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joerg Thomas Bittenbring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joerg Thomas Bittenbring. The network helps show where Joerg Thomas Bittenbring may publish in the future.

Co-authorship network of co-authors of Joerg Thomas Bittenbring

This figure shows the co-authorship network connecting the top 25 collaborators of Joerg Thomas Bittenbring. A scholar is included among the top collaborators of Joerg Thomas Bittenbring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joerg Thomas Bittenbring. Joerg Thomas Bittenbring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Secondary hemophagocytic lymphohistiocytosis associated with adjuvant pembrolizumab therapy in a young patient with triple-negative breast cancer: a case report with literature review 2025 ·Archives of Gynecology and Obstetrics ·(unknown), Meletios P. Nigdelis, (unknown), (unknown), Moritz Bewarder, Joerg Thomas Bittenbring, N Kranzhöfer, Lorenz Thurner, Yong‐Jae Kim, Anita Seibold, (unknown)	1
2	Hyper-N-glycosylated SEL1L3 as auto-antigenic B-cell receptor target of primary vitreoretinal lymphomas 2024 ·Scientific Reports ·(unknown), Frank Neumann, (unknown), Konstantinos Christofyllakis, (unknown), Igor Age Kos, (unknown), Dominic Kaddu‐Mulindwa, Joerg Thomas Bittenbring, Natalie Fadle, Evi Regitz, Falko Fend, Irina Bonzheim, Lorenz Thurner, Moritz Bewarder	1
3	Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritis 2024 ·Immunology Letters ·(unknown), Natalie Fadle, Evi Regitz, Igor Age Kos, (unknown), (unknown), Klaus‐Dieter Preuss, (unknown), (unknown), Vincent Zimmer, Philipp Klemm, G. Aßmann, (unknown), Joerg Thomas Bittenbring, Moritz Bewarder, Thomas Vogt, Claudia Pföhler, (unknown), Christoph Kessel, Lorenz Thurner	2
4	Real‐world effectiveness of first‐line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy 2024 ·European Journal Of Haematology ·(unknown), Jörg Chromik, (unknown), Sebastian Wolf, (unknown), (unknown), Julius C. Enßle, (unknown), Martin Sebastian, Björn Steffen, Thomas Oellerich, Hubert Serve, Andreas Neubauer, Jonas Schäfer, Joerg Thomas Bittenbring	4
5	Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP 2023 ·Haematologica ·Moritz Bewarder, Dominic Kaddu‐Mulindwa, Igor Age Kos, (unknown), Gerhard Held, Viola Poeschel, Lorenz Thurner, Joerg Thomas Bittenbring, Norbert Schmitz, Lorenz Truemper, Michael Pfreundschuh, Konstantinos Christofyllakis, Markus Loeffler, Bettina Altmann, Marita Ziepert	2
6	Vitamin D Enhances Immune Effector Pathways of NK Cells Thus Providing a Mechanistic Explanation for the Increased Effectiveness of Therapeutic Monoclonal Antibodies 2023 ·Nutrients ·Konstantinos Christofyllakis, Frank Neumann, Moritz Bewarder, Lorenz Thurner, Dominic Kaddu‐Mulindwa, Igor Age Kos, (unknown), Joerg Thomas Bittenbring	5
7	Adaptive humoral immune response and cellular immune status in cancer patients and patients under immunosuppression vaccinated against SARS-CoV-2 2022 ·Expert Review of Vaccines ·Igor Age Kos, (unknown), (unknown), (unknown), Joerg Thomas Bittenbring, Manfred Ahlgrimm, Sigrun Smola, Stefan Lohse, Konstantinos Christofyllakis, Dominic Kaddu‐Mulindwa, Frank Neumann, Moritz Bewarder, Lorenz Thurner	1
8	Advances in Lymphoma Molecular Diagnostics 2021 ·Diagnostics ·Igor Age Kos, Lorenz Thurner, Joerg Thomas Bittenbring, Konstantinos Christofyllakis, Dominic Kaddu‐Mulindwa	4
9	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome 2021 ·Blood ·Lorenz Thurner, Natalie Fadle, Joerg Thomas Bittenbring, Evi Regitz, (unknown), (unknown), (unknown), (unknown), Niels Murawski, Viola Poeschel, Dominic Kaddu‐Mulindwa, Klaus‐Dieter Preuss, Stephan Stilgenbauer, Olivier Hermine, Hanneke C. Kluin‐Nelemans, Sylvia Hartmann, Martin Dreyling, Christiane Pott, Moritz Bewarder, Eva Hoster	7
10	Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial 2021 ·Leukemia & lymphoma ·Dominic Kaddu‐Mulindwa, (unknown), Christian Berdel, Stephan Stilgenbauer, Moritz Bewarder, Lorenz Thurner, Mathias Witzens‐Harig, Andreas Viardot, Martin Soekler, Ulrich Keller, Lorenz Truemper, Konstantinos Christofyllakis, (unknown), Joerg Thomas Bittenbring, Viola Poeschel, Gerhard Held, (unknown)	2
11	Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE 2021 ·Pharmaceuticals ·Amir Sabet, (unknown), Joerg Thomas Bittenbring, Fadi Khreish, Frank Grünwald, H.-J. Biersack, Samer Ezziddin	2
12	VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B‐cell lymphoma 2020 ·European Journal Of Haematology ·Dominic Kaddu‐Mulindwa, Maciej Rosołowski, Marita Ziepert, Evi Regitz, G. Aßmann, Moritz Bewarder, Gerhard Held, Michael Pfreundschuh, Joerg Thomas Bittenbring	4
13	Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples 2020 ·European Journal of Clinical Microbiology & Infectious Diseases ·Sophie Roth, Fabian K. Berger, Andreas Link, (unknown), Philipp M. Lepper, Niels Murawski, Joerg Thomas Bittenbring, Sören L. Becker	4
14	Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential 2020 ·Cancer Immunology Immunotherapy ·Moritz Bewarder, Gerhard Held, Lorenz Thurner, Stephan Stilgenbauer, Sigrun Smola, Klaus‐Dieter Preuss, (unknown), (unknown), Konstantinos Christofyllakis, Joerg Thomas Bittenbring, (unknown), (unknown), Niels Murawski, Dominic Kaddu‐Mulindwa, Frank Neumann	4
15	Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation 2019 ·Bone Marrow Transplantation ·(unknown), Eva Domingo‐Doménech, Ariane Boumendil, Fina Climent, Gèrard Socié, Frank Kroschinsky, Hervé Finel, (unknown), Dan Nemet, Matthias Stelljes, Joerg Thomas Bittenbring, Stephen Robinson, Silvia Montoto, Anna Sureda, Peter Dreger	6
16	Vitamin D deficiency in head and neck cancer patients – prevalence, prognostic value and impact on immune function 2018 ·OncoImmunology ·Florian Bochen, (unknown), (unknown), Joerg Thomas Bittenbring, Frank Neumann, (unknown), Klaus Bumm, (unknown), Silke Wemmert, (unknown), (unknown), (unknown), Basel Al Kadah, Bernhard Schick, Maximilian Linxweiler	47
17	Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis 2018 ·Bone Marrow Transplantation ·Vipul Sheth, Myriam Labopin, Jonathan Canaani, Liisa Volin, Arne Brecht, Arnold Ganser, Jiřı́ Mayer, Hélène Labussière‐Wallet, Joerg Thomas Bittenbring, Roni Shouval, Bipin N. Savani, Mohamad Mohty, Arnon Nagler	15
18	Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity 2018 ·Cancer Immunology Immunotherapy ·Frank Neumann, (unknown), (unknown), Michael Pfreundschuh, Joerg Thomas Bittenbring	9
19	Integrated meta-omic analyses of the gastrointestinal tract microbiome in patients undergoing allogeneic hematopoietic stem cell transplantation 2017 ·Translational research ·Anne Kaysen, Anna Heintz‐Buschart, Emilie Muller, Shaman Narayanasamy, Linda Wampach, Cédric C. Laczny, Norbert Graf, Arne Simon, (unknown), Joerg Thomas Bittenbring, Paul Wilmes, Jochen G. Schneider	25
20	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation 2016 ·Biology of Blood and Marrow Transplantation ·Florent Malard, Myriam Labopin, Gernot Stuhler, Joerg Thomas Bittenbring, Arnold Ganser, Johanna Tischer, Mauricette Michallet, Nicolaus Kröger, Christoph Schmid, Anne Huynh, Michael Hallek, Bipin N. Savani, Mohamad Mohty, Arnon Nagler	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact